Personal view: Adequate relief as a primary endpoint in irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 7, 2006, Pages 879-881

  Mangel, A W ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; BENZODIAZEPINE DERIVATIVE; CILANSETRON; DEXTOFISOPAM; PLACEBO; TEGASEROD; UNCLASSIFIED DRUG;

CONVALESCENCE; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; HUMAN; IRRITABLE COLON; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION STUDY;

CLINICAL TRIALS; ENDPOINT DETERMINATION; HUMANS; IRRITABLE BOWEL SYNDROME; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 33645051979     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02839.x     Document Type: Review

References (13)

1. CPMP/EWP/785/97 Points to Consider on the Evaluation of Medicinal Products for the Treatment of Irritable Bowel Syndrome Also available at: (last accessed 19 March 2003)
2. Corazziari E Bytzer P Delvaux M et al. Consensus report: clinical trial guidelines for pharmacological treatment of irritable bowel syndrome Aliment Pharmacol Ther 2003 18 569 80
3. Camilleri M Mayer EA Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5HT3 receptor antagonist Aliment Pharmacol Ther 1999 13 1149 59
4. Camilleri M Northcutt AR Kong S. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial Lancet 2000 355 1035 40
5. Camilleri M Chey WY Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome Arch Intern Med 2001 161 1733 40
6. Miner P Stanton DB Carter F et al. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D); efficacy and safety in a 3 month US study Am J Gastroenterol 2004 99 S277
7. Leventer S Raudibaugh K Frissora C et al. The safety and efficacy of dextofisopam in patients with diarrhea-predominant or alternating irritable bowel syndrome Gastroenterology 2005 128 4 Suppl. 2 A94
8. Novick J Miner P Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation Aliment Pharmacol Ther 2002 16 1877 88
9. Muller-Lissner SA Fumagalli I Bardhan KD et al. Tegaserod, a 5HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Aliment Pharmacol Ther 2001 15 1655 66
10. Kellow J Lee OY Chang FY et al. An Asia-Pacific, double-blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod on patients with irritable bowel syndrome Gut 2003 52 671 6
11. Tack J Muller-Lissner S Bytzer P et al. A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation Gut 2005 54 1707 13
12. FDA Gastrointestinal Drugs Advisory Committee Transcript from FDA Gastrointestinal Drugs Advisory Committee Lotronex 1999 November 119
13. Mangel AW Hahn BA Heath AT et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome J Int Med Res 1998 26 76 81